The vaccine was well tolerated with mostly transient adverse events at the injection site.<h4>Conclusions</h4>RSV-vaccination led to a robust CD4 T-cell and humoral response in patients with CKD with less pronounced effects in those with high-grade proteinuria. This evidence concerns the gene CD4 and chronic kidney disease.